Introduction
Hypertension is one of the most important risk factors for heart attacks and strokes, which are mainly thrombus-related complications. 1 Although considerable research has been directed at the role of salt, the kidney, obesity, the renin-angiotensin system, and other endocrine influences in hypertension, the role of thrombogenic factors, including abnormalities in endothelial, platelet and haemorheological indices have not been fully explored. This is despite increasing evidence that hypertension may confer a prothrombotic or hypercoagulable state. 2 The aim of the present sub-study is to investigate the role of plasma markers of endothelial, platelet and haemorheological function in the aetiology of hypertension, their relationship with conventional risk factors and their value in refining risk stratification in patients screened and entered into the ASCOT study.
Background
Whilst the arterial tree is exposed to increased pressure, paradoxically the complications of hypertension are mainly thrombotic rather than haemorrhagic. Thus abnormalities of haemorheological indices, coagulation factors, arteriolar endothelial dysfunction and platelets may contribute to thrombus formation (thrombogenesis) in hypertensive Correspondence: Dr GYH Lip, Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK patients, thus creating a hypercoagulable state. There is evidence, for example, that prothrombotic and rheological (that is, blood flow) indices are abnormal in hypertensive patients even before they sustain any vascular complications and may therefore have some prognostic significance. As not all hypertensive patients sustain vascular damage, the identification and availability of laboratory indices that might aid prognostication would be useful. Furthermore, evidence derived from the measurement of markers of these processes should provide insight into the aetiology of hypertension and its complications, and also supply epidemiological data available for long-term follow-up studies.
A number of indices which can easily be measured in the labororatory have been noted to have associations with hypertension and cardiovascular risk.
Plasma viscosity and haematocrit:
Abnormal haemorheology, with raised plasma viscosity and haematocrit levels, has been demonstrated in many hypertensive populations. 3, 4 Furthermore, epidemiological studies in populations containing both hypertensive and normotensive individuals have found an increased risk of cardiovascular disease in those with higher mean plasma viscosity levels. 5, 6 Nevertheless, relatively little work has centred on the relationship between plasma viscosity, haematocrit and cardiovascular risk in hypertensive patients. There are limited data on changes in haematocrit with blood pressure control, but small trials of antihypertensive agents have found normalisation of plasma viscosity levels. Nevertheless, a large-scale comparison of traditional vs newer agents has not been performed.
Fibrinogen: Fibrinogen is a major determinant of plasma viscosity and as the precursor of fibrin, is a vital component of the blood coagulation system. Fibrinogen is positively correlated with blood pressure due to its contribution to increased plasma viscosity, which increases peripheral vascular resistance. 7 Many studies have demonstrated a clear relationship between increased plasma fibrinogen and cardiovascular disease risk. For example, the Atherosclerosis Risk in Communities study found an adjusted odds ratio for coronary heart disease between the highest and lowest tertiles of fibrinogen of 2.77 in men and 2.63 in women. 8 In the Leigh study, hypertensive subjects with plasma fibrinogen levels Ͼ3.5 g/l had a 12-fold higher cardiovascular risk than those with plasma fibrinogen levels Ͻ2.9 g/l. 9 von Willebrand Factor: As many of the complications of hypertension are produced through damage to the vessel wall a marker of endothelial damage may be valuable in risk stratification. von Willebrand Factor (vWF) has emerged as an important and readily measured marker of endothelial damage or dysfunction, and may also contribute to plasma viscosity. 10, 11 Higher levels of vWF have been demonstrated in patients with both hypertension, isolated systolic hypertension and systolic-diastolic hypertension, and furthermore levels may be reduced to normal by effective blood pressure reduction. In patients with other risk factors, however, vWF levels remained raised despite control of blood pressure. 12 One small study of 58 treated hypertensive patients reported that higher vWF levels predicted cardiovascular disease progression. 13 Soluble P-selectin: Platelet activation and aggregation plays a key role in thrombus formation and the interaction of the coagulation system with the damaged vascular endothelium. One plasma marker for platelet activation, soluble P-selectin provides a ready method for assessing the degree of platelet activation. Soluble P-selectin is raised in patients with hypertension.
14 Higher levels of Pselectin have also been reported in hypertensives with vascular damage. 15 All these abnormalities are consistent with a hypercoagulable (prothrombotic) state in hypertension, and are in keeping with the risks of cardiovascular disease, stroke and thromboembolism in hypertensives.
Many patients with uncontrolled hypertension develop evidence of 'end-organ' change, for example, left ventricular hypertrophy, renal damage, hypertensive retinopathy, etc. Such patients are at increased high risk of developing further complications, including strokes and heart attacks. The observation that satisfactory blood pressure reduction with non-drug intervention or various classes of antihypertensive drugs does not lead to an equal reduction in heart attacks and strokes may in part be due to unfavourable effects of some drugs on blood rheology and possibly, the coagulation system.
Some patients with hypertension also have hypercholesterolaemia, justifying the inclusion of a lipidlowering agent in the ASCOT design. Many of the arguments about the presence of hypertension are also true in patients with raised cholesterol levels. Elevated levels of vWf (implying vascular damage) are present in hyperlipidaemia patients and are reduced by successful treatment. 16 Hyperlipidaemia also provides a hypercoagulable state by promoting factor VIIa activity. 
Sub-study rationale
Risk factors such as diabetes, smoking, left ventricular hypertrophy (LVH), etc. greatly increase the cardiovascular risk in hypertension. Since the complications (heart attacks and strokes) of hypertension are thrombotic rather than haemorrhagic, does measurement of prothrombotic markers reflect the corresponding increase in risk which reflects increasing numbers of (clinical) risk factors?
Antihypertensive drugs may alter blood viscosity although their influence remains undefined. 18, 19 From the rheological aspect, drugs such as betablockers or calcium antagonists may have some favourable haemorheological actions. Particular benefits have been found for angiotensin-converting enzyme (ACE) inhibitor drugs in reducing platelet activation. 20 Treatment with ACE inhibitors and propanolol may also reduce platelet aggregation. The ACE inhibitor, perindopril, has also been promoted as having a beneficial effect on the endothelium. By contrast, the equivocal effects of beta-blockers and diuretics on platelets may have implications for the disappointing effect of these drugs in reducing coronary artery disease in hypertensive patients. The effects of 'old' (that is, betablockers and thiazides) vs 'new' (ACE inhibitors, calcium antagonists) antihypertensive agents will be compared in the ASCOT cohort.
Objectives
(1) To examine the relationship between prothrombotic markers and conventional risk factors in a cross-sectional study of patients screened for ASCOT with particular reference to the ability of prothrombotic markers to discriminate between 'high' and 'low' risk patients. (2) To assess whether the 'new' antihypertensive regime (amlodipine/perindopril) is superior to 'conventional' treatment (atenolol/bendroflu-methiazide) in reducing the prothrombotic state after 6 months therapy, taking into account the effects of intensified blood pressure control and whether this reduction is amplified by lipid lowering with a statin, compared with placebo.
Objective 1 will be addressed by a simple cohort design with appropriate correlations according to the number of risk factors on outset Objective 2 will be addressed in a follow-up study with visits according to the main ASCOT protocol.
Study methods and design

Ethics/consent
The study will be conducted according to the declaration of Helsinki. Approval has been obtained from the relevant local ethics committee. Consent issues are minimal as the study only involves the drawing of an additional 15 ml of blood when patients are already undergoing phlebotomy. We plan to recruit the majority of patients enrolled in ASCOT at the Birmingham centre into the sub-study. The target is 440 subjects for the follow-up study, in addition all patients who have a completed screening visit for ASCOT will be included in the cross-sectional study, thereby gathering data from approximately 250 additional subjects.
Recruitment
Recruitment will take part at the same time as recruitment into the main ASCOT study.
Inclusion and exclusion criteria
Inclusion and exclusion criteria will be the same as the main ASCOT study.
Study methods
At the screening visit an additional 15 ml of blood will be drawn and separated into serum, EDTA and citrate tubes. The citrated tubes will be centrifuged at 2000m rpm for 20 min and the plasma stored at −70°C. Soluble P-selectin and von Willebrand Factor will be measured at the Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, using validated ELISA techniques. Fibrinogen will be measured by the Clauss method and haemorheological indices (haematocrit and plasma viscosity) by routine autoanalyser at the haematology laboratory.
Data will be collected on the subjects cardiovascular risk factors as part of the ASCOT screening process.
At their visit 6 months after randomisation into ASCOT a further 15 ml of blood will be drawn from Journal of Human Hypertension subjects and repeat measurements of the prothrombotic markers will be performed.
Study numbers and statistical methodology
We have been conducting similar studies where the effect of intervening with various drugs (lipid-lowering, antihypertensive and anti-coagulant) in high risk patients is being tested. In such short-term (6 month) studies, we usually seek to recruit, for example, 30 subjects to each of two arms (active and placebo or primary and comparator) to provide sufficient power to define a difference of one half of one standard deviation in certain leading prothrombotic markers such as fibrinogen. The ASCOT subjects will be randomised in a factorial design to one of four groups, and as we seek to measure additional indices, a higher recruitment rate is required. We therefore calculate that we will need to have good follow up data from 440 subjects in order to be assured that we have sufficient participants in each arm.
This number (440) will also provide sufficient power to analyse the initial sample for objective 1. Here, we will stratify according to the number of risk factors. These will be hypertension as defined in the protocol, hypercholesterolaemia (cholesterol Ͼ6.5 mmol/L), diabetes, smoking and end-organ damage, such as LVH, etc. Clearly, there will be a reducing number of subjects as the number of risk factors increases. (All patients entered into ASCOT will have three risk factors, but some patients attending for screening but not actually entered will have Ͻ3 risk factors.)
Discussion
Hypertension remains a leading cause of premature death and disability in both the developed and developing world. The majority of these deaths are due to a thrombotic cause. Although the risks of hypertension can be reduced by effective treatment treated, in general hypertensives may remain at higher risk than normotensives. Nevertheless, data from the Glasgow Blood Pressure clinic suggests that mortality was high in the 1970s and 80s but has fallen since. 21 Trials of antihypertensive drugs have demonstrated that virtually all the excess risk of stroke attributable to hypertension may be ameliorated by treatment; however, the reduction in risk from coronary artery disease in trials performed prior to 1990 is less that expected from epidemiological studies.
1 Nevertheless in the Syst-Eur trial, using calcium antagonists and ACE inhibitors, there was a large reduction in coronary heart disease mortality. 22 The prothrombotic state in hypertension may be altered by drug therapy. Evidence from mainly small studies suggests that beta-blockers and calcium antagonists may have favourable haemorheological actions wheras diuretics may worsen plasma vis-cosity. 18, 19 Particular benefits on platelet activation have been suggested for ACE inhibitors. Indeed the failure of high dose duretics to reduce the incidence of myocardial infarction in the early hypertension trials may have been due to unfavourable effects on prothrombotic markers. We hope that this ASCOT sub-study will provide a unique opportunity to examine the differential effects of traditional and contemporary antihypertensive regimens in the context of a large randomised controlled trial.
Much emphasis has recently been placed on the estimation of absolute risk in making treatment decisions in hypertension. The use of computer programmes based on data from epidemiological studies of conventional risk factors (such as the Framingham risk score) has assisted in risk stratification but it remains necessary to treat large numbers of patients to prevent a single hypertension-related adverse event. We will investigate whether prothrombotic variables which have been shown to have prognostic significance in large epidemiological studies can be used to refine risk stratification in a typical hypertensive population and thus target intensified treatment at those most at risk.
Finally, research into platelet and endothelial function has often used techniques that are not readily applicable to everyday clinical situations because they are either invasive like forearm blood flow plethysmography using brachial artery infusions or not amenable to automation such as platelet aggregometry. The use of soluble plasma markers enables endothelial and platelet function to be studied in large numbers of hypertensive subjects in the ASCOT study, without the necessity for cumbersome invasive tests.
